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SUMMARY
Purpose: Compression of the spinal nerve roots by lumbar spinal stenosis is a major clinical 
problem associated with intermittent claudication, pain and numbness. The pathological mechanism is 
reduced blood flow in nerve roots and degeneration of nerve roots. Prostaglandin E1 （PGE1） is used 
for patients with peripheral arterial disease （PAD） to increase capillary flow around the main artery 
and improve symptoms; however, the ankle-brachial index （ABI） does not change after treatment. 
Lumbar spinal nerve roots contain somatosensory, somatomotor, and unmyelinated autonomic 
nerves, and improved blood flow in these spinal nerve roots may improve the function of nerve fibers 
innervating muscle, capillary, and main vessels in the lower leg, resulting in an increased ABI. The 
purpose of the study was to examine the hypothesis that limaprost, a PGE1 analog, improves blood 
flow in compressed and degenerated spinal nerve roots, leading to improved function of sympathetic 
and parasympathetic nerves in spinal nerve roots innervating the lower leg and a resultant increase in 
the ABI.
Methods: Limaprost （15 µg 3 times a day for 3 months） was administered orally to 49 patients 
with lumbar spinal stenosis. Low back pain and leg pain scores, walking distance, and ABI were 
measured before treatment and after 3 months of limaprost treatment.
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Ⅰ．Introduction
 Compression of spinal nerve roots by lumbar spinal 
stenosis （LSS） is a major clinical problem associated 
with intermittent claudication, pain, numbness, and 
lack of normal sensitivity［1,2］. Such compression has 
been shown to induce neurophysiologic dysfunction, 
degeneration, and reduced blood flow in nerve roots in 
animal models and in humans［1,2］. Drug therapy is 
often used in patients with mild to moderate symptoms, 
mainly with administration of nonsteroidal anti-
inflammatory drugs （NSAIDs）［3,4］.
 Reduced blood flow in nerve roots induces 
neurogenic intermittent claudication, and drugs for 
improvement of blood flow in nerve roots have been 
developed. Prostaglandin E1 （PGE1） causes vasodilation 
in both arterioles and venules［5,6］. In a clinical study, 
intravenous lipo-PGE1 administered for 10 consecutive 
days to 40 patients produced symptomatic improvement 
for a limited period in treatment of neurogenic intermittent 
claudication associated with lumbar spinal stenosis［7］. 
An investigation of 25 cases of lumbar spinal stenosis by 
myeloscopy revealed that the diameters of blood vessels 
in the cauda equina differed significantly from those in a 
control group［8］. In a separate study, myeloscopy also 
showed elimination of morphological changes in vessels 
along the cauda equina after administration of lipo-
PGE1 in patients who originally had vessel dilation on 
the surface of the cauda equina［9］. These human studies 
show that PGE1 improved the microcirculation in spinal 
nerve roots and relieved symptoms in patients with lumbar 
spinal stenosis.
 Patients with peripheral arterial disease （PAD） 
may be asymptomatic or present with a spectrum 
of symptoms including atypical leg pain, classic 
claudication, rest pain, and critical limb ischemia with 
gangrene［10］. PAD is diagnosed by assessing the 
ankle-brachial blood pressure index （ABI）, a rapid and 
simple non-invasive diagnostic technique［10］. Exercise 
and drugs such as PGE1, cilostazol （a selective inhibitor 
of phosphodiesterase III and an antiplatelet drug）, and 
angiotensin II type 1 （AT1） receptor blockers improve 
the symptoms of PAD［10］. In general, these drugs 
increase flow in capillary vessels and do not effect the 
main arterial tract. Thus, most reports have shown that 
these therapies improve symptoms, but do not influence 
ABI［11,12］.
 The lumbar spinal ventral nerve roots and dura 
mater include somatic and autonomic nerves such as 
unmyelinated sympathetic and parasympathetic nerves 
that innervate the lower leg［13-15］. Therefore, we 
hypothesized that treatment with limaprost, a PGE1 
analog, would increase blood flow on the surface of 
compressed and damaged spinal nerves, and that this 
would improve the function of somatosensory, motor 
and autonomic nerves innervating the main artery in the 
lower leg and lead to an increase in ABI. Improvement 
of blood flow in the lower leg after therapy for lumbar 
spinal stenosis has not been examined previously. 
Therefore, the purpose of the current study was to 
investigate the effect of limaprost on symptoms of 
lumbar spinal stenosis and on ABI.
Ⅱ．Methods
 The ethics committee of our institution approved the 
Results: Low back pain, leg pain, and maximum walking distance significantly improved after 
limaprost treatment （P＜0.05）. ABI was also significantly increased by limaprost treatment （P＝
0.003）.
Conclusions: This is the first investigation of changes in ABI in patients with lumbar spinal 
stenosis after treatment with a PGE1 analog. Our findings suggest that it is important to consider the 
role of the autonomic nervous system in spinal nerve roots associated with blood supply to the lower leg 
in patients with lumbar spinal stenosis.
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43Prostaglandin E1 improves pain and ABPI
protocol for the human procedures used in this study. 
Informed written consent was obtained from each subject.
Patients
 The subjects were patients with low back and leg 
pain that had continued for at least 1 month. Patients 
who had previously undergone spinal surgery were 
excluded from the study. We also excluded patients 
with spinal tumor, infection, or trauma. Lumbar spinal 
stenosis was diagnosed on X-ray and magnetic resonance 
imaging （MRI） and by physical examination by spine 
surgeons. On MRI, the degree of spinal stenosis varied 
from slight to severe, and central stenosis, stenosis of 
the lateral recess, and foraminal stenosis were apparent. 
Patients with monoradiculopathy, polyradiculopathies, 
or cauda equine syndrome were included in the study. 
The background of the subjects is shown in Table 1.
Administration of limaprost
 Oral limaprost （15 µg 3 times a day for 3 months） 
was given to all patients for treatment of lumbar spinal 
stenosis. For control of low back pain and leg pain, 
NSAIDs and vitamins were permitted and a spinal nerve 
block such as a transforaminal epidural block or caudal 
epidural block was also allowed （Table 1）.
Evaluation of pain scores and walking distance before 
and after treatment
 The JOA Back Pain Evaluation Questionnaire 
（JOABPEQ: including low back pain, lumbar function, 
walking ability, social life function and mental health） 
and a visual analogue scale （VAS: from 0 to 10, 10: 
worst） were evaluated for each patient. The range of 
the JOABPEQ score for each domain is from 0 to 100, 
with higher scores indicating a better condition. The five 
functional scores are used independently. Maximum 
walking distance without rest, total walking distance in 
a day, low back pain, and leg pain were evaluated before 
and 3 months after treatment. 
Determination of ABI
 Systolic blood pressures in the brachial, anterior and 
posterior tibial arteries were measured using inflatable 
cuffs and a Doppler probe. The maximum ankle arterial 
pressure was divided by the maximum brachial arterial 
pressure to calculate the ABI. ABI was measured 
according to the Transatlantic Inter Society Consensus 
（TASC II） guidelines for management of PAD［16］.
Statistical Analysis
 A paired t-test, Wilcoxon test, and MacNemar 
test were used to compare pain scales and ABI before 
and after treatment. P ＜0.05 was considered to be 
significant.
Ⅲ．Results
Patient background
 The background of the 49 patients in the study is 
shown in Table 1. Age ranged from 40 to 80 years old, 
with an average age of 68.06±9.13 years old （mean±
S.D.）. The average body mass index was 23.74. Among 
the patients, 18.4% were smokers. Complications 
included diabetes （18.4%）, hyperlipemia （12.2%）, 
hypertension （36 .7%）,  and vascular occlusion 
Table 1　Demographic characteristics
Item Value
Number of patients 49
Sex （male/female） 25/24
Height （cm） 159.01
Weight （Kg） 60.05
BMI 23.74
Age: mean ± SD 
（range） （years）
68.06±9.13 （40-80）
Symptom duration, mean 
（range） （months）
3.0 （1-24）
Other complications （n） 30
Diabetes 18.4%
Hyperlipemia 12.2%
Hypertension 36.7%
Vascular occlusion
Cerebral 4.1%
Coronary 4.1%
Peripheral 4.1%
Medication 
NSAIDs 53.1%
Vitamins 30.6%
Muscle relaxants 4.1%
Epidural block
Transforaminal epidural block 16.3%
Caudal epidural block 2.0%
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（cerebral, 4.1%; coronary, 4.1%; and peripheral, 
4.1%）. All patients received conservative treatment 
and medication （in addition to limaprost） was given to 
55.4% of the patients. NSAIDs were the most common 
additional drugs, and vitamins and muscle relaxants 
were also used. Transforaminal epidural block （16.3%） 
or caudal epidural block （2.0%） was performed for low 
back pain or leg pain.
Changes in pain scores and walking distance
 VAS scores for low back pain, buttock pain, and leg 
pain were 36.41±33.19, 44.95±33.37, and 66.95±
21.17, respectively, before administration of limaprost, 
and 22.45±29.40, 18.58±23.59, and 43.95±30.04, 
respectively, after administration of limaprost for 3 
months. Each score showed a significant improvement 
after treatment with limaprost （P＜0.01） （Table 2）. 
JOABPEQ scores for the 49 patients in 5 categories （low 
back pain, lumbar function, walking ability, social life 
function, and mental health） are also shown in Table 2. 
All categories significantly improved after 3 months of 
limaprost treatment （low back pain: P＜0.001, lumbar 
function; P＝0.002, walking ability: P＝0.004, social 
life function: P＜0.001, and mental health: P＜0.001）. 
There was also a significant improvement in maximum 
walking distance without rest from before to after 
treatment （550.21±1024.26 vs. 721.46±1023.79 m, 
P＝0.025）, but there was no significant improvement in 
walking distance in one day after treatment （P＝0.148） 
（Table 2）.
Change in ABI
 The average ABI was improved significantly by 
treatment with limaprost for 3 months （1.09±0.10 vs. 
1.12±0.12, P＝0.003） （Table 2）.
Ⅳ．Discussion
 In the current study, limaprost improved low back 
pain, leg pain, and walking difficulty that originated 
from lumbar spinal stenosis, and also increased ABI. 
These findings indicate that limaprost is useful to treat 
symptoms of lumbar spinal stenosis and to increase 
blood flow in the anterior and posterior tibial arteries.
 PGE1 is a vasodilator that increases blood flow and 
inhibits platelet aggregation［5］. Intravenous PGE1 is 
primarily used for chronic peripheral arterial occlusive 
diseases in the United States and Europe［5］. PGE1 
also increases blood flow at the surface of spinal nerve 
roots, and thus PGE1 analogs have been developed to 
treat symptoms of lumbar spinal stenosis［5,17］. These 
drugs include limaprost, an oral PGE1 analog that was 
developed in Japan. The efficacy of oral limaprost was 
evaluated in adult Japanese patients in 3 randomized, 
double-blind, 6-week trials［17］. Limaprost at a dose of 
15 µg/day was superior to a dose of 3 µg/day for overall 
Table 2　Pain scores, walking distance and ABI before and after 3 months of treatment with limaprost
Before After 3 months p value
VAS
Low back pain 36.41±33.19 22.45±29.40 　0.018
Buttock pain 44.95±33.37 18.58±23.59 　0.001
Leg pain 66.95±21.17 43.95±30.04 ＜0.001
JOABPEC
Low back pain 60.62±36.60 74.70±34.65 ＜0.001
Lumbar function 63.77±31.04 72.46±26.05 　0.002
Walking ability 42.86±31.32 56.83±32.45 　0.004
Social life 44.26±19.49 56.76±22.44 ＜0.001
Mental health 44.66±15.30 53.79±14.07 ＜0.001
Walking distance （m）
Maximum walking distance 
without rest
550.21±1024.26 721.46±1023.79 　0.025
Walking distance in one day 1349.05±1572.14 1541.43±1424.20 　0.148
ABI 1.09±0.10 1.12±0.12 　0.003
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and the dura mater［15］. Animal and human cadaver 
studies have shown that lumbar and sacral spinal ventral 
nerve roots contain many unmyelinated nerve fibers and 
sympathetic and parasympathetic nerves that innervate 
blood vessels in the lower leg［13,14］, with no significant 
difference in the proportions of unmyelinated nerve fibers 
among sympathetic （T11-L2）, parasympathetic （S2） and 
other （C4-T10 and L3-S1） segments［14］. Sympathetic 
and parasympathetic nerve fibers may be damaged and 
compressed in patients with lumbar canal stenosis, and 
increased blood flow to the spinal nerve roots caused 
by limaprost may result in recovery of function of the 
autonomic nervous system. Thus, this may explain the 
increase in ABI after treatment with limaprost in the 
current study.
 There were several limitations in the study. First, we 
did not use a control group taking NSAIDs only. Second, 
a normal ABI falls in the range of 0.91-1.30, while a 
low ABI at rest （＜0.90） indicates a high risk of PAD
［22］. In the current study, most patients had ABI in the 
normal range and the clinical significance of an increase 
of ABI in this population is questionable. Therefore, 
a further study is needed to test our hypothesis more 
rigorously. Within these limitations, we conclude that 
limaprost improved low back and leg pain originating 
from lumbar spinal stenosis, and increased ABI scores. 
These findings indicate that limaprost is useful to treat 
symptoms caused by lumbar spinal stenosis and blood 
flow in the main artery in the lower leg.
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